Hopes for new Alzheimer’s treatment dashed as drug misses clinical trial targets
An immunotherapy drug hailed as a potential game changer in the treatment of Alzheimer’s has missed its targets in a large-scale clinical trial. The antibody treatment, solanezumab, failed to achieve
Read More